Denosumab, a humanized monoclonal RANKL antibody, which could play a crucial role in different physiological activity including the prevention of skeletal-related events arising from cancer [28], was FDA approved for breast cancer, prostate cancer and so on [29], but had not been studied in endometrial cancer. Here, TNFSF11 is linked to endometrial cancer.